History of lower-limb complications and risk of cancer death in people with type 2 diabetes

Table 5 Risk of incident cancers according to history of lower-limb complications at baseline

		Incident cancers, n (%)		Model 1		Model 2
		No, n	Yes, n (%)	Hazard ratio (95% CI)	p	Hazard ratio (95% CI)	p
Lower-limb complication	No	6490	357 (5.2)	1.34 (1.15–1.56)	0.0001	1.23 (1.05–1.44)	0.01
Lower-limb complication	Yes	3950	343 (8.0)	1.34 (1.15–1.56)	0.0001	1.23 (1.05–1.44)	0.01
Peripheral arterial disease	No	8214	487 (5.6)	1.32 (1.12–1.56)	0.001	1.20 (1.01–1.43)	0.04
Peripheral arterial disease	Yes	2226	213 (8.7)	1.32 (1.12–1.56)	0.001	1.20 (1.01–1.43)	0.04
Peripheral neuropathy	No	7699	468 (5.7)	1.24 (1.06–1.45)	0.008	1.14 (0.97–1.35)	0.11
Peripheral neuropathy	Yes	2741	232 (7.8)	1.24 (1.06–1.45)	0.008	1.14 (0.97–1.35)	0.11

Model 1: age (and its square), sex, region of origin, and study allocations
Model 2: model 1 plus duration of diabetes, body mass index (and its square), waist circumference (and its square), systolic and diastolic blood pressure (and their squares), HbA1c (and its square), urinary ACR, eGFR (and its square), total cholesterol, HDL cholesterol, triglycerides, MMSE score, education accomplishment, history of ever or current smoking, history of past or current alcohol drinking, history of CAD, cerebrovascular disease, diabetic retinopathy or dementia, and use of metformin, insulin, antihypertensive, statin or antiplatelet therapy

ISSN: 1475-2840